Here, we report on two independent, flow cytometric methods of calculating CCR5 RO using the anti-CCR5 antibody, Leronlimab. However, current methods to measure CCR5 RO lack sensitivity, resulting in high background and overcalculation. The level of CCR5 receptor occupancy (RO) achieved by a CCR5-targeting therapeutic is therefore a critical predictor of its efficacy. Notably, CCR5 is the major HIV entry co-receptor, where its surface density correlates with HIV plasma viremia. 3CytoDyn Inc., Vancouver, WA, United StatesĬCR5 plays a central role in infectious disease, host defense, and cancer progression, thereby making it an ideal target for therapeutic development.2Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR, United States.1Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States.Bochart 2, Jeremy Smedley 2, Christopher P. Sylwester 1, David Morrow 1, Karina Belica 1, Miranda Fischer 2, Scott Kelly 3, Nader Pourhassan 3, Rachele M. Reed 1, Joseph Hwang 1, Courtney Waytashek 1, Carla Boyle 1, Cleiton Pessoa 1, Andrew W. Webb 1, Meenakshi Tiwary 1, Colette Hughes 1, Jason S.
0 kommentar(er)
